Ovoca Bio plc

OVXA

IE00B4XVDC01

Biotechnology & Medical Research

Real-time Irish S.E. Other stock markets 16:55:00 15/07/2024 BST			5-day change	1st Jan Change
0.01 ^EUR	0.00%		0.00%	0.00%

07-15	Jet2 chair buys; Ovoca Bio's old CEO sells to new	AN
07-15	Ovoca Bio CEO to Resign in August; Successor Named	MT

Ovoca Bio plc Announces Resignation of Kirill Golovanov as Executive Director, Effective 1 August 2024

July 15, 2024 at 07:00 am

Ovoca Bio plc announced that Kirill Golovanov has informed the Board of his intention to resign from his role as an Executive Director of the Company, with effect from 1 August 2024.

Latest news about Ovoca Bio plc

Jet2 chair buys; Ovoca Bio's old CEO sells to new	07-15	AN
Ovoca Bio CEO to Resign in August; Successor Named	07-15	MT
Ovoca Bio plc Announces CEO Changes, Effective 1 August 2024	07-15	CI
Ovoca Bio plc Announces Resignation of Kirill Golovanov as Executive Director, Effective 1 August 2024	07-15	CI
EARNINGS: AssetCo proposes name change; i(x) Net Zero eyes AIM exit	07-03	AN
Ovoca Bio plc Reports Earnings Results for the Full Year Ended December 31, 2023	06-28	CI
Ovoca Bio : Enrolls First Patient in Phase 2 Trial for Hypoactive Sexual Desire Disorder Treatment	29/01/21	MT

Ovoca Bio Plc is a biopharmaceutical company specialized in the development and manufacturing of peptides for the treatment of female sexual dysfunction. At the end of 2022, the Group had a product in phase III clinical development (Orenetide).

Sector

Biotechnology & Medical Research

Calendar

25/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
OVOCA BIO PLC	0.00%	890K
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	127B
ARGENX SE	+25.18%	27.67B
BIONTECH SE	-20.17%	20.33B
GENMAB A/S	-17.03%	16.79B
BEIGENE, LTD.	-18.07%	15.63B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.43B
INSMED INCORPORATED	+149.98%	12.49B